DOCSLIB.ORG

A Single Intramuscular Injection of Monoclonal Antibody MAD0004J08

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Single Intramuscular Injection of Monoclonal Antibody MAD0004J08 medRxiv preprint doi: https://doi.org/10.1101/2021.08.03.21261441; this version posted August 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy 2 adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and 3 vaccination 4 Simone Lanini1, Stefano Milleri2, Emanuele Andreano3, Sarah Nosari4, Ida Paciello3, Giulia Piccini5, Alessandra 5 Gentili7, Adhuna Phogat8, Inesa Hyseni5,6, Margherita Leonardi5,6, Alessandro Torelli5, Emanuele Montomoli5,6,10, 6 Andrea Paolini8,9, Andrea Frosini8, Andrea Antinori1, Emanuele Nicastri1, Enrico Girardi1, Maria Maddalena 7 Plazzi1, Giuseppe Ippolito1, Francesco Vaia1, Giovanni Della Cioppa11, Rino Rappuoli3, 12,* 8 9 1Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani – IRCCS, Rome, Italy 10 2Centro Ricerche Cliniche di Verona, University and Hospital Trust of Verona, Verona, Italy 11 3Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy 12 4AchilleS Vaccine, Siena, Italy 13 5VisMederi S.r.l, Siena, Italy 14 6VisMederi Research S.r.l, Siena, Italy 15 7CROss Research, Mendrisio, Switzerland 16 8Fondazione Toscana Life Sciences, Siena, Italy 17 9Toscana Life Sciences Sviluppo, Siena, Italy 18 10Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy 19 11Clinical R&D Consultants, Rome, Italy 20 12 Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy 21 22 *Correspondence to Dr. Rino Rappuoli 23 Email: [email protected] 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.08.03.21261441; this version posted August 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 24 Summary 25 Background: The emerging threat represented by SARS-CoV-2 variants, demands the development of therapies for 26 better clinical management of COVID-19. MAD0004J08 is an extremely potent Fc-engineered monoclonal antibody 27 (mAb) able to neutralise in vitro all current SARS-CoV-2 variants of concern (VoCs). This ongoing study, evaluates 28 safety, pharmacokinetics and SARS-CoV-2 sera neutralization effect of MAD0004J08 when administered as single 29 dose intramuscularly in healthy adults. 30 31 Method: We conducted a dose escalation study with sequential enrolment of three cohorts, each with an increasing 32 dose level of MAD0004J08 (48mg, 100mg and 400mg). Within each cohort, 10 young healthy adults were 33 randomized with 4:1 ratio to a single intramuscular (i.m.) injection of MAD0004J08 or placebo. The primary 34 endpoint is the proportion of subjects with severe and/or serious treatment emergent adverse events (TEAEs) within 35 7 days post-treatment. Secondary endpoints reported in this paper are the proportion of subjects with solicited 36 TEAEs up 7 days post dosing, MAD0004J08 serum concentrations and neutralising activity versus the original 37 SARS-COV-2 Wuhan virus at different timepoints post-dosing. As post-hoc analyses, we compared the sera 38 neutralising titres of subjects who received MAD0004J08 with those of people that had received the COVID-19 39 BNT162b2 mRNA vaccine in the previous sixty days (n=10) and COVID-19 convalescent patients (n=20), and 40 assessed serum neutralisation activity against the B.1.1.7 (alpha), B.1.351 (beta) and B.1.1.248 (gamma) SARS- 41 CoV-2 variants of concern. 42 43 Findings: A total of 30 subjects, 10 per cohort, were enrolled and randomized. Data up to 30 days were available 44 and analysed in this report. No severe TEAEs were reported in any of the cohorts in the 7 days post-treatment. 45 MAD0004J08 was detected in the sera of treated subjects within few hours post-administration and reached almost 46 maximal levels on day 8. The geometric mean neutralising titres (GMT) assessed against the original Wuhan virus 47 peaked on day 8 and ranged 226 – 905, 905 – 2,560, and 1,280 – 5,120 for cohort 1, 2 and 3 respectively. The sera 48 neutralising GMT in MAD0004J08 treated subjects in all the three cohorts were found to be 1·5- 54·5-fold higher 49 compared to sera from convalescent patients and 1·83– 76·4-fold higher compared to sera from COVID-19 50 vaccinees. Finally, GMT in MAD0004J08 treated subjects showed high neutralising titres versus the B.1.1.7 (alpha), 51 B.1.351 (beta) and B.1.1.248 (gamma) SARS-CoV-2 VoCs. 52 53 Interpretation: A single dose administration of MAD0004J08 via i.m. route is safe and well tolerated and results in 54 a rapid systemic distribution of the MAD0004J08 and sera neutralising titres higher than COVID-19 convalescent 55 and vaccinated subjects. A single dose administration of MAD0004J08 is also sufficient to effectively neutralise 56 major SARS-CoV-2 variants of concern. Based on these results, a Phase 2-3 trial is ongoing to further assess the 57 safety, dosage, and efficacy of MAD0004J08 in asymptomatic or mild-moderate symptomatic COVID-19 patients. 58 59 Funding: EU Malaria Fund, Ministero dello Sviluppo Economico, Ministero della Salute, Regione Toscana, 60 Toscana Life Sciences Sviluppo and European Research Council. 2 medRxiv preprint doi: https://doi.org/10.1101/2021.08.03.21261441; this version posted August 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 61 Research in context 62 Evidence before this study 63 We searched PUBMED, MEDLINE and MedRxiv for clinical trials, meta-analyses and randomized controlled trials 64 evaluating the antibody neutralization titres vs. different SARS-CoV-2 variants of concern obtained from subjects 65 who received monoclonal antibodies for the treatment of COVID-19 using the following search terms: (“COVID- 66 19” OR “SARS-CoV-2”) AND (“monoclonal antibody” OR "neutralising antibody") AND ("variants" OR "variants 67 of concern"). No relevant studies were identified. 68 69 Added value of this study 70 This is the first human study assessing safety, PK and neutralising potential of MAD0004J08, a monoclonal 71 antibody against SARS-CoV-2 wild type Wuhan virus and variants of concern, administered intramuscularly at low 72 dosages (48, 100 and 400 mg). MAD0004J08 showed to be safe and well tolerated in the tested dose range. Anti- 73 spike antibodies were detected in the sera of tested SARS-CoV-2 negative healthy adults few hours post-injection. 74 In addition, the sera obtained from MAD0004J08treated subjects, showed to have high neutralisation titres against 75 the Wuhan virus, the B.1.1.7 (alpha), B.1.351 (beta) and B.1.1.248 (gamma) variants of concern. 76 77 Implications of all the available evidence 78 A potent monoclonal antibody such as MAD0004J08, capable of neutralising multiple variants of concern of SARS- 79 CoV-2 rapidly and long lastingly when given as a single intramuscular injection. The antibody, presently tested in a 80 phase 2-3 efficacy trial, can be a major advancement in the prophylaxis and clinical management of COVID-19, 81 because of its broad spectrum, ease of use in non-hospital settings and economic sustainability. 3 medRxiv preprint doi: https://doi.org/10.1101/2021.08.03.21261441; this version posted August 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 82 Introduction 83 The COVID-19 pandemic highlighted the potential of human monoclonal antibodies (mAbs) to tackle pandemics as 84 they demonstrated to be safe and effective therapeutic tools that can be brought from discovery to proof-of-concept 85 trials in only 5 – 6 months1. Since the start of the pandemic a dozen mAbs capable of neutralising the SARS-CoV-2 86 virus have been identified and are under clinical development. Regulatory agencies have granted Emergency Use 87 Authorization (EUA) to Eli Lilly’s mAb bamlanivimab (LY-CoV555) and mAb combination bamlanivimab + 88 etesevimab, to Regeneron’s mAb combination casiribimab + imdevimab (REGN-COV2), to Celltrion regdanvimab, 89 and GSK/VIR sotrovimab.2-5 With the emergence of antibody-resistant SARS-CoV-2 variants of concern (VoCs) at 90 the end of 2020, some mAbs lost their clinical efficacy and in April 2021 the FDA revoked EUA for bamlanivimab.6 91 The Toscana Life Sciences Foundation has recently reported the isolation and characterization of the neutralising 92 mAb, MAD0004J08 from a convalescent COVID-19 patient.7 MAD0004J08 appears to be the best candidate for 93 clinical development as it displays the most desirable characteristics for the development of mAb-based prophylaxis 94 and therapy: 1) unprecedented high neutralising potency, implying low dose requirement, intramuscular route of 95 administration, and significant cost reduction of cost of goods. 2) breadth of neutralising activity, in vitro vs. the 96 original Wuhan virus and all current SARS-CoV-2 VoC; B.1.1.7 (alpha), B.1.351 (beta), B.1.1.248 (gamma) and 97 B.1.617.2 (delta) with a potency below 10 ng/mL (7 and manuscript in preparation), implying broad clinical 98 usefulness in countries with diverse SARS-CoV-2 epidemiology.
Load more

Recommended publications
  • Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 5 Issue 7 July 2021 Review Article Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic Abhishek Kumar Yadav, Shubham Kumar and Vikramdeep Monga* Received: May 02, 2021 Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, Published: June 09, 2021 India © All rights are reserved by Vikramdeep *Corresponding Author: Vikramdeep Monga, Department of Pharmaceutical Monga., et al. Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 or coronavirus disease 2019 and the same has been declared as a global pandemic by WHO which marked the third introduction of a virulent coronavirus into human society. This a threat to human life worldwide. Considerable efforts have been made for developing effective and safe drugs and vaccines against is a highly pathogenic human coronavirus in which pneumonia of unknown origin was identified in China in December 2019 and is SARS-CoV-2. The current situation and progress in the development of various therapeutic candidates including vaccines in preclini- cal and clinical studies have been described in the manuscript. Until now, many people have been infected with this lethal virus, and a lot of people have died from this COVID-19. This viral disease spreads by coming in contact with an infected person. Understand- ing of SARS-CoV-2 is growing in relation to its epidemiology, virology, and clinical management strategies. Till date, very few drugs or vaccines have been developed or approved for the treatment of this deadly disease of COVID-19 and many candidates are under the clinical development pipeline.
    [Show full text]
  • Policy Brief 002 Update 07.2021
    Content ................................................................................................................................................................ 3 1 Background: policy question and methods ................................................................................................. 7 1.1 Policy Question ............................................................................................................................................. 7 1.2 Methodology ................................................................................................................................................. 7 1.3 Selection of Products for “Vignettes” ........................................................................................................ 10 2 Results: Vaccines ......................................................................................................................................... 13 2.1 Moderna Therapeutics—US National Institute of Allergy ..................................................................... 25 2.2 University of Oxford/ Astra Zeneca .......................................................................................................... 26 2.3 BioNTech/Fosun Pharma/Pfizer .............................................................................................................. 27 2.4 Janssen Pharmaceutical/ Johnson & Johnson .......................................................................................... 29 2.5 Novavax ......................................................................................................................................................
    [Show full text]
  • Regdanvimab for the Treatment of COVID-19
    25 March 2021 EMA/192245/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation (EC) No 726/2004 Celltrion use of regdanvimab for the treatment of COVID-19 INN/active substance: regdanvimab Procedure number: EMEA/H/A-5(3)/1505 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical aspects .................................................................................................... 4 2.2.1. Clinical pharmacology ........................................................................................ 6 2.2.2. Data on efficacy ...............................................................................................
    [Show full text]
  • May 2021 Monitoring International Trends
    Monitoring International Trends May 2021 The NBA monitors international developments that may influence the management of blood and blood products in Australia. Our focus is on: Potential new product developments and applications; Global regulatory and blood practice trends; Events that may have an impact on global supply, demand and pricing, such as changes in company structure, capacity, organisation and ownership; and Other emerging risks that could put financial or other pressures on the Australian sector. Highlights include: Research and development in the health sector, and clinical trials, continue to have a strong focus on pandemic related matters, although other issues are receiving more attention than a year ago. Professional societies are holding virtual conferences and annual meetings. Some developments in treating blood disorders (hereditary angioedema, paroxysmal nocturnal haemoglobinuria, and haemophilia) are described on page 3. Hereditary angioedema patients in the United States, the European Union and Japan now have the option of oral prophylaxis rather than injection or infusion. Researchers reinforced the view that the use of tranexamic acid in hip and knee arthroplasties could reduce blood transfusions (page 3). Others found that intravenous immunoglobulin did not relieve the pain of idiopathic small fibre neuropathy (page 4). Some scientists are estimating the life of antibodies in people who have had a COVID-19 infection (page 4), others are trialling the efficacy of monoclonal antibodies in treating the disease (pages 4 and 5), and there is interest in what is termed “long COVID” (page 4). With a number of COVID-19 vaccines in large-scale use, discussion continues about their effectiveness against a variety of variants, their possible side effects, whether they should be used sequentially in the same patients, how much they permit break-through infection, whether they prevent disease transmission to others, how long the immunity they produce will last and whether boosters will be required (pages 6 to 9).
    [Show full text]
  • Policy Brief 002 Update 04.2021.Pdf
    .................................................................................................................................................................. 3 1 Background: policy question and methods ................................................................................................. 7 1.1 Policy Question ............................................................................................................................................. 7 1.2 Methodology ................................................................................................................................................. 7 1.3 Selection of Products for “Vignettes” ........................................................................................................ 10 2 Results: Vaccines ......................................................................................................................................... 13 2.1 Moderna Therapeutics—US National Institute of Allergy ..................................................................... 22 2.2 University of Oxford/ Astra Zeneca .......................................................................................................... 23 2.3 BioNTech/Fosun Pharma/Pfizer .............................................................................................................. 25 2.4 Janssen Pharmaceutical/ Johnson & Johnson .......................................................................................... 27 2.5 Novavax ......................................................................................................................................................
    [Show full text]
  • Korean Society of Infectious Diseases/National Evidence-Based
    Infect Chemother. 2021 Jun;53(2):395-403 https://doi.org/10.3947/ic.2021.0304 pISSN 2093-2340·eISSN 2092-6448 Special Article Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS- CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19 Sun Bean Kim 1,*, Jimin Kim 2,*, Kyungmin Huh 3, Won Suk Choi 1, 4 5 6 1 Received: Jun 8, 2021 Yae-Jean Kim , Eun-Jeong Joo , Youn Jeong Kim , Young Kyung Yoon , Jung Yeon Heo 7, Yu Bin Seo 8, Su Jin Jeong 9, Su-Yeon Yu 2, Corresponding Author: Kyong Ran Peck 3, Miyoung Choi 2, Joon Sup Yeom 9, and Joon-Sup Yeom, MD, DTM&H, PhD Korean Society of Infectious Diseases (KSID) Department of Internal Medicine, Yonsei University College of Medicine, Yonsei-ro 50-1, 1Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seodaemun-gu, Seoul 03722, Korea. Seoul, Korea Tel: 82-2-2228-1942 2Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare, Fax: 82-2-393-6884 Collaborating Agency, Seoul, Korea E-mail: [email protected] 3Division of Infectious Diseases, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Miyoung Choi, MPH, PhD 4Division of Infectious Diseases and Immunodeficiency, Department of Pediatrics, Samsung Medical Center, Division of Healthcare Technology Assessment Sungkyunkwan University School of Medicine, Seoul, Korea Research, National Evidence-based 5Division of Infectious Diseases, Department of Internal Medicine, Sungkyunkwan University School of Healthcare Collaborating Agency, Namsan Medicine, Kangbuk Samsung Hospital, Seoul, Korea Square 7F, 173 Toegye-ro, Jung-gu, Seoul 6Division of Infectious Diseases, Department of Internal Medicine, Incheon St.
    [Show full text]
  • Medizinische Biotechnologie in Deutschland 2021
    BIOTECH-REPORT Medizinische Biotechnologie in Deutschland 2021 Biopharmazeutika: Wirtschaftsdaten und Therapiefortschritte durch Antikörper Die Boston Consulting Group (BCG) ist eine internationale Managementberatung und weltweit führend auf dem Gebiet der Unternehmensstrategie. BCG unterstützt Unternehmen aus allen Branchen und Regionen dabei, Wachstumschancen zu nutzen und ihr Geschäftsmodell an neue Gegebenheiten anzupassen. In partner schaftlicher Zusammenarbeit mit den Kunden entwickelt BCG individuelle Lösun gen. Gemeinsames Ziel ist es, nachhaltige Wettbewerbsvorteile zu schaffen, die Leistungsfähigkeit der Unternehmen zu steigern und das Geschäftsergebnisda uer haft zu verbessern. BCG wurde 1963 von Bruce D. Henderson gegründet und ist heute an mehr als 90 Standorten in über 50 Ländern vertreten. Das Unternehmen befindet sich im alleinigen Besitz seiner Geschäftsführer*innen. Weitere Informationen finden Sie auf unserer Internetseite www.bcg.de. Foto: DNA strands background: © Fotolia, Fotograf*in: Zffoto #104622650 Foto: Human antibody: © Fotolia, Fotografin: Tatiana Shepeleva #94084192 Der vfa ist der Wirtschaftsverband der forschenden Pharma-Unternehmen in Deutschland. Er vertritt die Interessen von 47 weltweit führenden forschenden Pharma-Unternehmen und über 100 Tochter- und Schwesterfirmen in der Gesundheits-, Forschungs- und Wirtschaftspolitik. Die Mitglieder des vfa repräsentieren mehr als zwei Drittel des gesamten deutschen Arzneimitt el- marktes und beschäftigen in Deutschland rund 80.000 Mitarbeiter*innen. Sie gewährleisten
    [Show full text]
  • Interim Clinical Guidance for Adults with Suspected Or Confirmed Covid-19 in Belgium
    INTERIM CLINICAL GUIDANCE FOR ADULTS WITH SUSPECTED OR CONFIRMED COVID-19 IN BELGIUM September 2021; Version 22 Preliminary note COVID-19 is a mild viral illness in the vast majority of the patients (80%) but may cause severe pneumonitis and disseminated endotheliitis [1] (and subsequent complications) with substantial fatality rates in elderly and individuals with underlying diseases. About 20% of infected patients need to be admitted, including 5% who require intensive care. This document is periodically revised to provide support to the diverse groups of Belgian clinicians (general practitioners, emergency physicians, infectious disease specialists, pneumologists, intensive care physicians) who have to face suspected/confirmed COVID-19 cases during the epidemic in Belgium. This guideline primarily targets hospital care but refers whenever necessary to other guidelines. The guidance has been developed from March to December 2020 by a task force of Infectious Diseases Specialists (IDS): Dr Sabrina Van Ierssel, Universitair Ziekenhuis Antwerpen; Dr Nicolas Dauby, Hôpital Universitaire Saint-Pierre Bruxelles; Dr Emmanuel Bottieau, Instituut voor Tropische Geneeskunde (ITG), and Dr Ralph Huits, ITG, supported by Sciensano (Dr Chloe Wyndham-Thomas;), the AFMPS/FAGG (Dr Roel Van Loock) and ad-hoc contributions from colleagues of other disciplines. Since January 2021, the COVID-19 therapeutic guideline has officially been taken over by the Belgian Society of Infectiology and Clinical Microbiology (BVIKM/SBIMC), and the new task force is composed of IDS representatives from all Belgian University Hospitals, with the additional collaboration of the Belgian Societies of Intensive Care Medicine and of Pneumology. The complete list of members is available below. This guidance is based on the best clinical evidence (peer-reviewed scientific publications) that is available at the moment of writing each update, and is purposed to be a “living guideline” which can always be found via the same link.
    [Show full text]
  • COVID-19: Unmasking Emerging SARS-Cov-2 Variants, Vaccines and Therapeutic Strategies
    biomolecules Review COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies Renuka Raman 1,† , Krishna J. Patel 2,† and Kishu Ranjan 3,* 1 Department of Surgery, Weill Cornell Medical College, New York, NY 10065, USA; [email protected] 2 Mount Sinai Innovation Partners, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; [email protected] 3 School of Medicine, Yale University, New Haven, CT 06519, USA * Correspondence: [email protected]; Tel.: +1-203-785-3588 † Authors contributed equally to this work. Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major concern for global human health. The challenge to restrain the COVID-19 pandemic is further compounded by the emergence of several SARS-CoV-2 variants viz. B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta), which show increased transmissibility and resistance towards vaccines and therapies. Importantly, there is convincing evidence of increased susceptibility to SARS-CoV-2 infection among individuals with dysregulated immune response and comorbidities. Herein, we provide a comprehensive perspective regarding vulnerability of SARS-CoV-2 infection in patients with underlying medical comorbidities. We discuss ongoing vaccine (mRNA, protein-based, viral vector-based, etc.) and therapeutic (monoclonal antibodies, small molecules, plasma therapy, etc.) modalities designed to curb the COVID-19 pandemic. We also discuss in detail, the challenges posed by different SARS-CoV-2 variants of concern (VOC) identified across the globe and their effects on therapeutic and prophylactic interventions.
    [Show full text]
  • Regdanvimab for the Treatment of COVID-19 (Celltrion) Art. 5(3
    ANNEX I CONDITIONS OF USE, CONDITIONS FOR DISTRIBUTION AND PATIENTS TARGETED AND CONDITIONS FOR SAFETY MONITORING ADRESSED TO MEMBER STATES FOR UNAUTHORISED PRODUCT Regkirona (regdanvimab) AVAILABLE FOR USE 1 1. MEDICINAL PRODUCT FOR USE . Name of the medicinal product for Use: Regkirona . Active substance(s): Regdanvimab . Pharmaceutical form: Concentrate for solution for infusion . Route of administration: Intravenous infusion . Strength: 60 mg/ml 2. NAME AND CONTACT DETAILS OF THE COMPANY Celltrion Healthcare Hungary Kft. 1062 Budapest Váci út 1-3. WestEnd Office Building B torony Hungary Tel: +36-1-231-0493 Fax: +36-1-231-0494 Email: [email protected] 3. TARGET POPULATION Regdanvimab is indicated for the treatment of confirmed COVID-19 in adult patients that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID- 19. Risk factors may include but are not limited to: • Advanced age • Obesity • Cardiovascular disease, including hypertension • Chronic lung disease, including asthma • Type 1 or type 2 diabetes mellitus • Chronic kidney disease, including those on dialysis • Chronic liver disease • Immunosuppressed, based on prescriber’s assessment. Examples include: cancer treatment, bone marrow or organ transplantation, immune deficiencies, HIV (if poorly controlled or evidence of AIDS), sickle cell anaemia, thalassaemia, and prolonged use of immune-weakening medications. 4. CONDITIONS FOR DISTRIBUTION Medicinal product subject to medical prescription. 5. CONDITIONS OF USE Regdanvimab may only be administered in settings in which health care providers have immediate access to medicinal products to treat a severe infusion reaction, such as anaphylaxis. Limitation in Patients with Severe COVID-19 Monoclonal antibodies, such as regdanvimab may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation with COVID-19.
    [Show full text]
  • Neutralizing Antibody Therapeutics for COVID-19
    viruses Review Neutralizing Antibody Therapeutics for COVID-19 Aeron C. Hurt 1,* and Adam K. Wheatley 2 1 F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland 2 Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; [email protected] * Correspondence: [email protected]; Tel.: +41-79-105-9786 Abstract: The emergence of SARS-CoV-2 and subsequent COVID-19 pandemic has resulted in a significant global public health burden, leading to an urgent need for effective therapeutic strate- gies. In this article, we review the role of SARS-CoV-2 neutralizing antibodies (nAbs) in the clinical management of COVID-19 and provide an overview of recent randomized controlled trial data evaluating nAbs in the ambulatory, hospitalized and prophylaxis settings. Two nAb cocktails (casiriv- imab/imdevimab and bamlanivimab/etesevimab) and one nAb monotherapy (bamlanivimab) have been granted Emergency Use Authorization by the US Food and Drug Administration for the treat- ment of ambulatory patients who have a high risk of progressing to severe disease, and the European Medicines Agency has similarly recommended both cocktails and bamlanivimab monotherapy for use in COVID-19 patients who do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19. Efficacy of nAbs in hospitalized patients with COVID-19 has been varied, potentially highlighting the challenges of antiviral treatment in patients who have already progressed to severe disease. However, early data suggest a promising prophylactic role for nAbs in providing effective COVID-19 protection. We also review the risk of treatment-emergent antiviral resistant “escape” mutants and strategies to minimize their occurrence, discuss the susceptibility of newly emerging SARS-COV-2 variants to nAbs, as well as explore administration challenges and Citation: Hurt, A.C.; Wheatley, A.K.
    [Show full text]
  • Policy Brief 002 Update 06.2021
    Content ................................................................................................................................................................ 3 1 Background: policy questi on and met hods ................................................................................................. 7 1.1 Policy Question ............................................................................................................................................. 7 1.2 Methodology ................................................................................................................................................. 7 1.3 Selection of Products for “Vignettes” ........................................................................................................ 10 2 Results: Vacci nes ......................................................................................................................................... 13 2.1 Moderna Therapeutics—US National Institute of Allergy ..................................................................... 24 2.2 University of Oxford/ Astra Zeneca .......................................................................................................... 24 2.3 BioNTech/Fosun Pharma/Pfizer .............................................................................................................. 25 2.4 Janssen Pharmaceutical/ Johnson & Johnson .......................................................................................... 27 2.5 Novavax ......................................................................................................................................................
    [Show full text]